Accessibility navigation


From fibroblasts to medicinal signalling cells: a paradigm shift in translational stem cell research

Sheard, J., Ramasamy, T. S. and Widera, D. (2018) From fibroblasts to medicinal signalling cells: a paradigm shift in translational stem cell research. Drug Target Review, 2018 (2). pp. 42-44. ISSN 2059-1349

[img] Text - Accepted Version
· Restricted to Repository staff only
· The Copyright of this document has not been checked yet. This may affect its availability.

764kB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Abstract/Summary

Mesenchymal stem cells (MSCs) are the most intensely studied type of adult stem cells. Their presence in virtually all vascularised tissues, easy accessibility, good tolerability and safety profile along with the lack of ethical issues has raised a considerable clinical and commercial interest. In this review, we describe the changing views on this cell population and highlight the paradigm shift in its translational use from direct transplantation to the application of MSC-derived paracrine factors with MSCs acting as `Medicinal Signalling Cells` or natural biofactories. Moreover, we summarise current strategies aiming at replacing MSC transplantation with the use of soluble factors and extracellular vesicles secreted by this clinically relevant stem cell type.

Item Type:Article
Refereed:No
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:80250
Publisher:Russel Publishing

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation